Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study

• Published in: Maturitas Vol. 81; no. 1; pp. 46 - 56
• Main Authors: Labrie, Fernand, Archer, David F, Bouchard, Céline, Girard, Ginette, Ayotte, Normand, Gallagher, John C, Cusan, Leonello, Baron, Mira, Blouin, François, Waldbaum, Arthur S, Koltun, William, Portman, David J, Côté, Isabelle, Lavoie, Lyne, Beauregard, Adam, Labrie, Claude, Martel, Céline, Balser, John, Moyneur, Érick
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 01.05.2015
• Subjects: Administration, Intravaginal; Adult; Aged; Atrophy - complications; Atrophy - drug therapy; Dehydroepiandrosterone; Dehydroepiandrosterone - administration & dosage; Double-Blind Method; Dyspareunia - drug therapy; Dyspareunia - etiology; Female; Hormones - administration & dosage; Humans; Internal Medicine; Local action; Middle Aged; Obstetrics and Gynecology; Postmenopause; Prasterone; Pruritus - drug therapy; Secondary symptomatology; Severity of Illness Index; Sexual Behavior; Vagina - pathology; Vaginal Diseases - complications; Vaginal Diseases - drug therapy; Vulva - pathology; Vulvar Diseases - complications; Vulvar Diseases - drug therapy; Vulvovaginal atrophy; Dehydroepiandrosterone; Local action; Prasterone; Secondary symptomatology; Vulvovaginal atrophy
• ISSN: 0378-5122; 1873-4111
• DOI: 10.1016/j.maturitas.2015.02.005

Highlights • Dyspareunia, dryness and irritation/itching were evaluated. • Intravaginal prasterone (0.50%, 6.5 mg) was administered daily for 52 weeks. • All three moderate/severe (MS) symptoms respond in parallel to treatment. • The choice of one MS symptom as most bothersome does not affect the response.